Plasma Cell Neoplasm — Variants & evidence

Plasma Cell Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

53 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 51–53 of 53 evidence items (3 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MYC Overexpression1
JQ-1	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	5	accepted	EID5505 BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic mal… (full text at CIViC) PMID 21889194 · Delmore et al., 2011 · Open in CIViC	civic
NRAS Mutation1
(prognostic)	Multiple Myeloma	Prognostic	B	Supports N/A	4	accepted	EID496 In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival. PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic
TNFRSF17 Gain1
(oncogenic)	Multiple Myeloma	Oncogenic	B	Supports Oncogenicity	1	submitted	EID9226 Low coverage WGS and WES was performed on 752 multiple myleoma patients. Structural variants (copy number gains, templated insertions, and or translocations) of TNFRS17 were found in 19 (2.5%) patient… (full text at CIViC) PMID 33392515 · Rustad et al., 2020 · Open in CIViC	civic

Data updated 8 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.